PWPS
HRTX icon

Pinnacle Wealth Planning Services’s Heron Therapeutics HRTX Stock Holding History

Pinnacle Wealth Planning Services’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$76 Hold
178
– – ﹤0.01% 2734
2026
Q1 		$142 Hold
178
– – ﹤0.01% 2708
2025
Q4 		$231 Buy
+178
New +$220 ﹤0.01% 2706

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Pinnacle Wealth Planning Services's HRTX Position: Q2 2026 in Review

Pinnacle Wealth Planning Services held its Heron Therapeutics (HRTX) position steady in Q2 2026 at 178 shares worth $76. The position accounts for ﹤0.01% of the portfolio, ranked #2734.

Pinnacle Wealth Planning Services first reported a position in HRTX in Q4 2025 and has held it in 3 quarters since. The position peaked at $231 in Q4 2025. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Pinnacle Wealth Planning Services held 178 shares of Heron Therapeutics worth $76 as of Q2 2026.
  • Pinnacle Wealth Planning Services left its Heron Therapeutics share count unchanged in Q2 2026.
  • Heron Therapeutics made up ﹤0.01% of Pinnacle Wealth Planning Services's portfolio in Q2 2026, its #2734 holding.
  • Pinnacle Wealth Planning Services first reported a position in Heron Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Pinnacle Wealth Planning Services's Heron Therapeutics position peaked at $231 in Q4 2025.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Pinnacle Wealth Planning Services's 13F filing for Q2 2026, filed 7 Aug 2026.